LAVA Therapeutics N.V.
LVTX
$1.52
$0.010.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -148.32% | 12.37% | 67.71% | -48.13% | -1,265.13% |
| Total Depreciation and Amortization | -92.52% | 148.64% | -203.77% | 76.67% | -16.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.98% | -359.82% | -146.91% | 526.53% | 28.46% |
| Change in Net Operating Assets | -36.83% | -195.91% | 190.87% | 445.89% | 41.64% |
| Cash from Operations | -18.07% | -728.83% | 83.72% | -5.06% | -874.38% |
| Capital Expenditure | -- | -- | 100.00% | -200.00% | 200.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -400.00% | -33.33% | -96.63% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -118.34% | 38.10% | 2,245.51% | 38.87% | -46.34% |
| Cash from Investing | -116.47% | 38.17% | 2,354.36% | 23.14% | -47.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -85.59% | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -87.50% | 100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 44.02% | -2,400.00% | 100.00% |
| Foreign Exchange rate Adjustments | 157.82% | 187.54% | -405.61% | 261.51% | 70.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -385.34% | -42.14% | 199.13% | -0.28% | -675.86% |